



Medicinal Chemistry

Ashutosh Kar



Medicinal Chemistry

Ashutosh Kar



ANSHAN LTD

6 Newlands Road
Tunbridge Wells
Kent.
TN4 9AT. UK

Co-published in the U. K. by

ANSHAN LTD, 6 Newlands Road, Tunbridge Wells, Kent TN4 9AT
In 2006

Tel/Fax: +44(0)1892 557767
e-mail: info@anshan.co.uk
Web Site: www.anshan.co.uk

© 2006 by New Age International Pvt. Ltd.

ISBN 1 904798 764
ISBN 978 1904798 767

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by means, electronics, mechanical photocopying, recording and/or otherwise, without the prior written permission of the publishers.

British Library Cataloguing in Publication Data
A Catalogue record for this book is available from the British Library

Not for sale in India, Pakistan, Sri Lanka, Bangladesh and Nepal.

Note - every effort has been made to ensure that the drug dosage schedules in this book are accurate and in accord with the standards accepted at the time of publication. However the reader is urged to consult drug manufacturer's printed instructions, particularly regarding the recommended dose, indications and contra-indications for administration and adverse reactions, before administering any of the drugs.

Medicinal Chemistry

CONTENTS

CHAPTER 1: Drug Design—A Rational Approach	1
1. Introduction	1
2. Analogues and Prodrugs	2
3. Concept of Lead	2
3.1. Examples	2
4. Factors Governing Drug-Design	5
5. Rational Approach to Drug-Design	5
5.1. Quantum Mechanical Approach	6
5.2. Molecular Orbital Approach	6
5.3. Molecular Connectivity Approach	6
5.4. Linear Free Energy Approaches	6
6. Drug-Design : The Method of Variation	6
6.1. Drug Design Through Disjunction	7
6.2. Drug Design Through Conjunction	9
7. Drug Design and Development: An Overview	10
7.1. Preamble	12
7.2. Revolutions in Drug Discovery	12
7.3. Research and Development Strategies	13
8. Molecular Hybridization	13
9. Rigidity and Flexibility Vs Drug Design	15
9.1. Increased Rigidity	15
9.2. Increased Flexibility	17
10. Tailoring of Drugs	17
11. General Considerations	17
CHAPTER 2: Physical-Chemical Factors and Biological Activities	19
1. Introduction	19
2. Physical Properties	20
2.1. Features Governing Drug Action in Active Site	20
2.2. Structurally Specific Drugs	20

2.3. Structurally Non-Specific Drugs	21
2.4. Thermodynamic Activity	21
2.5. Meyer-Overton and Meyer-Hemmi Theory	21
2.6. Ferguson's Theory	22
2.7. Van der Waal's Constants	22
2.8. The Cut-off Point	23
2.9. Steric Factors	24
2.9.1. Taft's Steric Factor (Es)	25
2.9.2. Molar Refractivity (MR)	28
2.9.3. Verloop Steric Parameter	29
2.10. Hansch Equation	30
2.11. The Craig Plot	32
2.12. The Topliss Scheme	33
3. Factors Governing Ability of Drugs to Reach Active Site	37
3.1. Absorption	37
3.2. Distribution	38
3.3. Metabolism (Biotransformation)	38
3.4. Excretion	39
3.5. Intramolecular Distances and Biological Activity	39
4. Dissociation Constants	40
4.1 Drug Exerting Action on Undissociated Molecules	40
4.2. Drugs Exerting Action on Ionized Molecules	41
5. Isosterism and Bio-Isosterism	41
5.1. Classical Bioisosteres	43
5.2. Nonclassical Bioisosteres	45
6. Stereochemistry and Drug Action	47
6.1. Enantiomers	47
6.2. Diastereoisomers	48
6.3. Stereochemistry and Biologic Activity	50
6.3.1. Positional Isomers (or Constitutional Isomers)	51
6.3.2. Geometrical Isomers	51
6.3.3. Absolute Configuration	52
6.3.4. Easson-Stedman Theory	52
6.3.5. Conformationally Flexible to Conformationally Rigid Molecule	52
7. Chemical Properties	53
7.1. Molecules Negentropy	53
7.2. Cammarata Correlation	53

CHAPTER 3: General Anaesthetics	55
--	-----------

1. Introduction	55
2. Classification	55
2.1. Inhalation Anaesthetics	55
2.2. Intravenous Anaesthetics	60
2.3. Basal Anaesthetics	65
3. Mode of Action of General Anaesthetics	67
3.1. Lipid Theory	67
3.2. Physical Theory	68
3.3. Biochemical Theory	68
3.4. Miscellaneous Theory	68
3.5. Meyer-Overton Theory	68
3.6. Minimum Alveolar Concentration (MAC)	68
3.7. Stereochemical Effects	69
3.8. Ion Channel and Protein Receptor Hypotheses	70
4. Mechanism of Action General Anaesthetics	70

CHAPTER 4: Local Anaesthetics	75
--------------------------------------	-----------

1. Introduction	75
2. Classification	78
2.1. The Esters	78
2.2. Piperidine or Tropane Derivatives	87
2.3. The Amides	90
2.4. The Quinoline and Iso-Quinoline Analogues	96
2.5. Miscellaneous Type	99
3. Chemical Considerations of Local Anaesthetic Drug Substances	102
3.1. Löfgren's Classification	102
3.1.1. Lipophilic Entity	103
3.1.2. Intermediate Chain	107
3.1.3. Hydrophilic Entity	107
4. Benzoic Acid and Aniline Analogues with Potential Local Anaesthetic Profile	108
5. Mode of Action of Some Selected Local Anaesthetics	111

CHAPTER 5: Sedatives and Hypnotics	116
---	------------

1. Introduction	116
-----------------	-----

2. Classification	117
2.1. Barbiturates	117
2.2. Non barbiturates	136
3. Mode of Action of Barbiturates	140
4. Mechanism of Action	140
5. Barbiturates Vs Benzodiazepines	141
6. Structure-Activity Relationship	141
7. Barbiturates Vs Dissociation Constant (pKa)	142
8. Substitutions on Hetero Atoms in Barbiturates	143
9. OH ⁻ Catalyzed Degradation of Barbiturates	143
10. Specific Mechanism of Action of Some Sedatives and Hypnotics	144

CHAPTER 6 : Anticonvulsants	148
------------------------------------	------------

1. Introduction	148
2. Classification	149
2.1. Barbiturates	149
2.2. Hydantoin Derivatives	150
2.3. Oxazolidinediones	153
2.4. Succinimides	154
2.5. Miscellaneous	158
3. Chemotherapy of Epilepsy	160
4. Mechanisms of Action for the Anticonvulsants	162
5. Specific Mechanisms of Selected Anticonvulsants	164

CHAPTER 7: Muscle Relaxants	168
------------------------------------	------------

1. Introduction	168
2. Classification	168
2.1. Neuromuscular Blocking Drugs	168
2.2. Centrally Acting Muscle Relaxants	177
3. General Mechanism of Action of Muscle Relaxants	186
4. Mode of Action of Some Specific Muscle Relaxants	189

CHAPTER 8: Central Nervous System Stimulants	194
---	------------

1. Introduction	194
2. Classification	195
2.1. Xanthine Derivatives	196

2.2. Analeptics	200
2.3. Miscellaneous Central Nervous System Stimulants	204
3. CNS-Peptides, S-Glutamate and Blockade of NMDA Induced Responses	207
3.1. CNS-Peptides	207
3.2. S-Glutamate and Blockade of NMDA-Induced Responses	208
4. Mechanism of Action of Selected CNS-Stimulants	209

CHAPTER 9: Antipyretic Analgesics	212
--	------------

1. Introduction	212
2. Classification	213
2.1. Aniline and <i>p</i> -Aminophenol Analogues	213
2.2. Salicylic Acid Analogues	217
2.3. Quinoline Derivatives	223
2.4. Pyrazolones and Pyrazolodiones	225
2.5. The N-Arylanthranilic Acids	232
3. Mechanism of Action	234
4. Mechanism of Action of Selected Antipyretic-Analgesics	235

CHAPTER 10: Narcotic Analgesics (Opiate Analgesics)	241
--	------------

1. Introduction	241
2. Limitations of Opiate Analgesics	242
3. Characteristics Features of Opioids	243
3.1. Opioid Peptides	243
3.2. Opioid Receptors	244
3.3. Orphan Opioid Receptors	244
3.4. Mu Opioid Receptors	244
3.5. Kappa Opioid Receptors	245
3.6. Delta Opioid Receptors	247
3.7. Opioid Receptors: Identification and Activation	248
4. Classification	249
4.1. Morphine Analogues	249
4.2. Morphinan Analogues	254
4.3. Morphan Analogues	257
4.4. 4-Phenylpiperidine Analogues	259
4.5. Phenylpropylamine Analogues	264
4.6. Miscellaneous Analogues	267

5. Narcotic Antagonists	269
6. Morphine: Structural Representations	271
7. Mechanism of Action of Certain Narcotic Analgesics	273

CHAPTER 11: Cardiovascular Drugs	279
---	------------

1. Introduction	279
2. Classification	280
3. Cardiac Glycosides	280
3.1. Designing the Cardiac Glycoside Receptor	280
3.2. Mechanism of Action	283
4. Antihypertensive and Hypotensive Drugs	283
4.1. Renin-Angiotensin Pathway	284
4.2. Angiotensin II Receptor Antagonists	284
4.3. Potential Dependent Calcium Channels	285
4.4. Mechanism of Action of Selected Antihypertensive and Hypotensive Drugs	289
5. Antiarrhythmic Agents	290
5.1. Membrane-Stabilizing Agents	293
5.1.1. Mechanism of Action of Membrane Stabilizing Agents	297
5.2. Antisymphathetic Drugs	298
5.2.1. Mechanism of Action	299
5.3. Prolonging Cardiac Action	299
5.3.1. Mechanism of Action	301
5.4. Interference with Calcium Conductance	301
5.4.1. Mechanism of Action	302
6. Vasopressor Drugs	302
6.1. Mechanism of Action	305

CHAPTER 12: Autonomic Drugs	308
------------------------------------	------------

1. Introduction	308
2. Classification	309
3. Sympathomimetic Drugs	309
3.1. Mechanism of Action	318
3.2. Structure Activity Relationships (SARs)	319
4. Beta Adrenergic Receptor Stimulants	320
4.1. Mechanism of Action	321

5. Adrenergic Receptor Blocking Agents	321
5.1. α -Adrenergic Blocking Agents	321
5.1.1. Mechanism of Action	325
5.2. β -Adrenoreceptor Blocking Agents	325
5.2.1. First Generation β -Blockers	326
5.2.2. Second Generation β -Blockers (selective β_1 -Blockers)	330
5.2.3. Third Generation β -Blockers	331
5.3. Alpha- and Beta-Adrenergic Receptor Blocking Agent	333
6. Cholinomimetic (Parasympathomimetic) Drugs	333
6.1. Directly Acting	333
6.2. Indirectly Acting (Anticholinesterase) Drugs	337
6.2.1. Mechanism of Action	341
7. Antimuscarinic (Anticholinergic) Agents	342
7.1. Aminoalcohol Esters	343
7.2. Aminoalcohol Ethers	350
7.3. Aminoalcohol Carbamates	351
7.4. Aminoalcohols	351
7.5. Aminoamides	351
7.6. Diamines	354
7.7. Miscellaneous Amines	354
7.8. Mechanism of Action	357
8. Ganglionic Blocking Agents	360
8.1. Mechanism of Action	364
9. Adrenergic Neurone Blocking Agents	365
9.1. Mechanism of Action	367

CHAPTER 13: Diuretics	370
------------------------------	------------

1. Introduction	370
2. Classification	370
2.1. Mercurial Diuretics	371
2.2. Non-Mercurial Diuretics	376
2.2.1. Thiazides (Benzothiazines)	376
2.2.2. Carbonic Anhydrase Inhibitors	388
2.2.3. Miscellaneous Sulphonamide Diuretics	394
2.2.4. 'Loop' and 'High-Ceiling' Diuretics	399
2.2.5. Aldosterone Inhibitors	403

2.2.6. Pyrimidine or Xanthine Diuretics	405
2.2.7. Pyrimidine Diuretics	406
2.2.8. Osmotic Diuretics	406
2.2.9. Acidotic Diuretics	409
2.2.10. Miscellaneous Diuretics	410

CHAPTER 14: Antihistamines	414
-----------------------------------	------------

1. Introduction	414
2. Classification	415
2.1. Histamine H ₁ -Receptor Antagonists	415
2.1.1. Aminoalkylethers	416
2.1.2. Ethylenediamines	420
2.1.3. Thiophene Derivatives	424
2.1.4. Cyclic Basic Derivatives	427
2.1.5. Phenothiazine Derivatives	431
2.1.6. Second Generation Nonsedating Antihistamines	435
2.1.7. Miscellaneous Agents	440
2.2. Prevention of Histamine Release	445
2.2.1. Mechanism of Action	446
2.3. Histamine (H ₂) Receptor Blockers	446
2.3.1. Mechanism of Action	447

CHAPTER 15: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	450
---	------------

1. Introduction	450
2. Classification	451
2.1. Heteroarylacetic Acid Analogues	451
2.1.1. Mechanism of Action	454
2.2. Arylpropionic Acid Analogues	455
2.2.1. Mechanism of Action	457
2.3. Arylpropionic Acid Analogues	458
2.3.1. Mechanism of Action	460
2.4. Naphthalene Acetic Acid Analogues	460
2.4.1. Mechanism of Action	461
2.5. Gold Compounds	461
2.5.1. Mechanism of Action	464

2.6. Miscellaneous Anti-Inflammatory Drugs	465
2.6.1. Antimalarial Agents	465
2.6.2. Uricosuric Agents	465
2.7. Salicylic Acid Analogues	469
2.8. Pyrazolones and Pyrazolodiones	469

CHAPTER 16: Antiparkinsonism Agents	471
--	------------

1. Introduction	471
1.1. Etiology	471
1.2. Parkinsonism Produced by MPTP	473
2. Classification	474
2.1. Piperidine Analogues	474
2.1.1. Mechanism of Action	477
2.2. Pyrrolidine Analogue	478
2.2.1. Mechanism of Action	479
2.3. Phenothiazine Analogue	479
2.3.1. Mechanism of Action	480
2.4. Miscellaneous Drugs	481
2.4.1. Mechanism of Action	485

CHAPTER 17: Expectorants and Antitussives	489
--	------------

1. Introduction	489
2. Classification	491
2.1. Sedative Expectorants	491
2.2. Stimulant (Irritant) Expectorants	494
2.3. Centrally Acting Antitussive Agents	496

CHAPTER 18: Sulphonamides	504
----------------------------------	------------

1. Introduction	504
2. Classification	506
2.1. Sulphonamides for General Infections	506
2.1.1. Mechanism of Action	514
2.2. Sulphonamides for Urinary Infections	517
2.2.1. Mechanism of Action	520
2.3. Sulphonanides for Intestinal Infections	520
2.3.1. Mechanism of Action	524

2.4. Sulphonamide for Local Infection	525
2.4.1. Mechanism of Action	526
2.5. Sulphonamide Related Compounds	526
2.5.1. Mechanism of Action	528
3. Ionization of Sulphonamides	529
4. Sulphonamide Inhibition and Probable Mechanisms of Bacterial Resistance to Sulphonamides	529
5. Chemotherapeutic Consideration	530

CHAPTER 19: Antimalarials	532
----------------------------------	------------

1. Introduction	532
2. Classification	534
2.1. 4-Aminoquinoline Analogues	534
2.1.1. Mechanism of Action	541
2.2. 8-Aminoquinoline Analogues	543
2.2.1. Mechanism of Action	551
2.3. 9-Aminoacridines	552
2.3.1. Mechanism of Action	556
2.4. Guanidine Analogues (Biguanides)	557
2.4.1. Mechanism of Action	560
2.5. Pyrimidine Analogues (Diaminopyrimidines)	560
2.5.1. Mechanism of Action	564
2.6. Sulfones	564
2.6.1. Mechanism of Action	565
2.7. Quinine Analogues	566
2.7.1. Mechanism of Action	566
2.8. New Antimalarial Drugs	566

CHAPTER 20: Anthelmintics	571
----------------------------------	------------

1. Introduction	571
2. Classification	572
2.1. Piperazines	573
2.2. Benzimidazoles	574
2.3. Heterocyclics	578
2.4. Antimalarials	579
2.5. Natural Products	579

CHAPTER 21: Insulin and Oral Hypoglycemic Agents	584
---	------------

1. Introduction	584
2. Insulin-Primary Structure	585
2.1. Variants of Insulin Products	586
3. Oral Hypoglycemic Agents	588
3.1. Sulfonylureas	588
3.1.1. First-Generation Sulfonylureas	588
3.1.2. Second-Generation Sulfonylureas	591
3.2. Non-Sulfonylureas-Metaglinides	593
3.3. Thiazolidinediones	595
3.4. Bisguanides	596
3.5. α -Glucosidase Inhibitors	597

CHAPTER 22: Steroids	600
-----------------------------	------------

1. Introduction	600
2. Steroid Nomenclature, Numbering, Double Bonds and Stereochemistry	600
3. Classification	603
3.1. Sterols	604
3.2. Sex Hormones	604
3.2.1. Classification	605
3.2.2. Androgens	605
3.2.3. Oestrogens	611
3.2.4. Gestogens	620
3.3. Cardiac Glycosides	623
3.3.1. Mechanism of Action	625
3.4. Bile Acids	626
3.5. Sapogenins	627

CHAPTER 23: Antibiotics	629
--------------------------------	------------

1. Introduction	629
2. Classification	630
3. β -Lactam Antibiotics	630
3.1. Penicillins	630
3.2. Cephalosporins	647
4. Aminoglycoside Antibiotics	656

5. Chloramphenicol	660
5.1. Structure of Chloramphenicol	660
5.2. Synthesis of Chloramphenicol	661
5.3. Structure Activity Relationship	663
6. Tetracyclines	664
6.1. Salient Features of Tetracyclines	664
6.2. Nomenclature	665
6.3. General Characteristics of the Tetracyclines	665
6.4. Structure Activity Relationship (SAR)	668
6.5. Newer Tetracyclines	669

CHAPTER 24: Antineoplastic Agents	672
--	------------

1. Introduction	672
1.1. Chemotherapeutic Intervention	674
1.1.1. Phase Specificity	674
1.1.2. Tumour Selectivity and Response	675
1.1.3. Determinants of Sensitivity and Selectivity	676
1.1.4. Requirements for Kill	677
1.1.5. Combination Chemotherapy	677
1.1.6. Log Cell-Kill Principle	677
1.1.7. Drug Resistance	678
2. Classification	678
2.1. Alkylating Agents	679
2.1.1. Mustards	679
2.1.2. Methanesulphonates	684
2.1.3. Ethylenimines	685
2.1.4. Nitrosoureas	686
2.2. Antimetabolites	688
2.2.1. Antifolic Acid Compounds	688
2.2.2. Analogues of Purines	690
2.2.3. Analogues of Pyrimidines	692
2.2.4. Amino Acid Antagonists	694
2.3. Antibiotics	695
2.3.1. Mechanism of Action	696
2.4. Plant Products	696
2.4.1. Imides and Amides	697
2.4.2. Tertiary Amines	698

2.4.3. Heterocyclic Amines	701
2.4.4. Lactones	701
2.4.5. Glycosides	702
2.5. Miscellaneous Compounds	703
2.5.1. Mechanism of Action	705
2.6. Hormones	706
2.6.1. Mechanism of Action	708
2.7. Immunotherapy	708
2.7.1. Mechanism of Action	709

CHAPTER 25: Antipsychotics (Tranquilizers)	712
---	------------

1. Introduction	712
2. Classification	713
2.1. Reserpine and Related Alkaloids	713
2.1.1. Mechanism of Action	714
2.2. Alkylene Diols	715
2.3. Diphenylmethane Compounds	715
2.3.1. Mechanism of Action	719
2.4. Phenothiazine Compounds	719
2.4.1. Mechanism of Action	722
2.5. Dibenzazepines	723
2.5.1. Mechanism of Action	724
2.6. Butyrophenones	725
2.6.1. Mechanism of Action	726
2.7. Azaspirodecanediones	726
2.7.1. Mechanism of Action	727

CHAPTER 26: Antiviral Drugs	729
------------------------------------	------------

1. Introduction	729
1.1. Replication and Transformation	730
2. Classification	730
2.1. Substances that Inhibit Early Stages of Viral Replication	730
2.1.1. Mechanism of Action	731
2.2. Substances that Interfere with Viral Nucleic Acid Replication	732
2.2.1 Mechanism of Action	734
2.3. Substances that Affect Translation on Cell Ribosomes	735
2.3.1. Mechanism of Action	736